No black box warning on record for Juluca

As of the latest FDA labeling reviewed, Juluca (DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Juluca medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Severe skin and hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported with the individual components. Discontinue JULUCA immediately if signs or symptoms of severe skin or hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening

No black box warning on record for Juluca

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Severe skin and hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported with the individual components. Discontinue JULUCA immediately if signs or symptoms of severe skin or hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening

Juluca Black Box Warning

No black box warning on record for Juluca

Other warnings & precautions

Juluca Black Box Warning

No black box warning on record for Juluca

Other warnings & precautions